McKesson Corp. (NYSE:MCK) – This company provides pharmaceutical supply management and information technologies. It acquired US Oncology in December.
MCK earned $4.29 in 2011 and is expected to earn $6.35 in 2012. The company is in a strong financial position with over $3.9 billion in cash and good cash flow. Of the 20 analysts covering MCK, 18 have either a “strong buy” or “buy” on the stock. And S&P targets the stock at $100.
Technically MCK has been consolidating around its 200-day moving average at just under $80.
McKesson was included in our Top Stocks to Buy for March, and yesterday the stock was up despite a broad market sell-off. Buy MCK on further market weakness at $80. A break above its May high of $88 should quickly propel it to our technical target of $105.